Gossamer Bio Inc (NAS:GOSS)
$ 0.6791 0.0091 (1.36%) Market Cap: 152.74 Mil Enterprise Value: 116.22 Mil PE Ratio: 0 PB Ratio: 5.63 GF Score: 37/100

Gossamer Bio Inc at Barclays Global Healthcare Conference Transcript

Mar 15, 2023 / 07:05PM GMT
Release Date Price: $1.32 (-5.71%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Okay. Good afternoon, and welcome to day 2 of the Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst here at Barclays. I am pleased to welcome Gossamer Bio to the stage. Joining us from the company is Bryan Giraudo, CFO and COO; as well as Rob Roscigno, VP of Clinical Development. Guys, thank you very much for joining us today.

Bryan Giraudo
Gossamer Bio, Inc. - COO & CFO

Great to be here. And as always, thanks for the invitation.

Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Bryan, I don't know if you want to make some opening comments, or we can just kind of jump into Q&A.

Bryan Giraudo
Gossamer Bio, Inc. - COO & CFO

I think real quickly -- I think it's a very exciting time for Gossamer, our friends at Merck's, data with sotatercept. It really is heralding a new era in the treatment of PAH. And we are, one, very

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot